DexCom (NASDAQ:DXCM) was downgraded by equities research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday, BidAskClub reports.

Several other research firms have also weighed in on DXCM. Cowen boosted their target price on shares of DexCom from $430.00 to $450.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. JPMorgan Chase & Co. boosted their target price on shares of DexCom from $360.00 to $450.00 and gave the company an “overweight” rating in a research note on Monday, July 27th. SVB Leerink boosted their target price on shares of DexCom from $465.00 to $485.00 and gave the company an “outperform” rating in a research note on Wednesday. Morgan Stanley boosted their target price on shares of DexCom from $377.00 to $428.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, BTIG Research reiterated a “hold” rating on shares of DexCom in a research note on Wednesday, April 29th. Seven investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. DexCom has a consensus rating of “Buy” and a consensus target price of $394.95.

Shares of NASDAQ:DXCM traded up $4.18 during midday trading on Thursday, reaching $435.54. The company had a trading volume of 865,127 shares, compared to its average volume of 922,371. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.58 and a quick ratio of 5.41. The stock’s fifty day moving average price is $410.52 and its 200-day moving average price is $325.07. The stock has a market capitalization of $41.70 billion, a P/E ratio of 198.88, a PEG ratio of 4.70 and a beta of 0.79. DexCom has a one year low of $138.28 and a one year high of $446.50.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, July 28th. The medical device company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.48. The business had revenue of $451.80 million during the quarter, compared to analyst estimates of $415.21 million. DexCom had a net margin of 11.93% and a return on equity of 29.01%. The business’s revenue was up 34.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.08 earnings per share. As a group, sell-side analysts forecast that DexCom will post 2.43 earnings per share for the current year.

In other DexCom news, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $344.63, for a total value of $2,067,780.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Andrew K. Balo sold 6,522 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $366.47, for a total transaction of $2,390,117.34. The disclosure for this sale can be found here. Over the last quarter, insiders sold 63,293 shares of company stock worth $24,266,963. 0.69% of the stock is owned by company insiders.

A number of institutional investors have recently modified their holdings of DXCM. Norges Bank bought a new stake in DexCom in the fourth quarter worth about $200,017,000. Sands Capital Management LLC acquired a new stake in DexCom during the 1st quarter worth about $134,008,000. Janus Henderson Group PLC raised its holdings in DexCom by 34.0% during the 1st quarter. Janus Henderson Group PLC now owns 784,992 shares of the medical device company’s stock worth $211,379,000 after buying an additional 199,106 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in DexCom by 45.3% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 557,647 shares of the medical device company’s stock worth $150,158,000 after buying an additional 173,794 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in DexCom by 600.1% during the 1st quarter. Russell Investments Group Ltd. now owns 176,047 shares of the medical device company’s stock worth $47,611,000 after buying an additional 150,902 shares during the period. Hedge funds and other institutional investors own 97.08% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: Total Return

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.